Skip to content

Author

H. Brink

We have 1 of 5 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Siglec-1-targeted nanobodies restrict HIV-1 transmission and infection of dendritic cells

Newly developed single-domain antibodies against Siglec-1 are used against Siglec-1 as a candidate inhibitor to limit HIV-1 transmission and support the development of host-directed nanobody-based strategies to reduce HIV-1 spread.

S. Man, A. Affandi, H. Brink et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.